The nucleoside analog clitocine is a potent and efficacious readthrough agent

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• Nonsense mutations in tumor suppressor genes are prevalent in many cancers.
• These mutations lead to premature stop codons, contributing to disease progression.
• Readthrough-inducing compounds offer a potential therapeutic strategy.

Purpose of the Study:

• To identify and characterize compounds that can induce readthrough of nonsense mutations.
• To evaluate the therapeutic potential of clitocine in cancer treatment.

Main Methods:

• Identified clitocine as a nucleoside analog with nonsense mutation readthrough activity.
• Investigated clitocine's mechanism of action, focusing on RNA incorporation.
• Assessed clitocine's ability to restore p53 protein production and function in cancer cells.
• Evaluated clitocine's efficacy in xenograft tumor models of ovarian cancer.

Main Results:

• Clitocine incorporation into RNA during transcription is essential for readthrough.
• Clitocine directly induces readthrough when present in the third position of a premature stop codon.
• Clitocine restored full-length, functional p53 protein in cells with p53 nonsense mutations.
• This restoration led to transcriptional activation, apoptosis, and impeded tumor growth in vivo.

Conclusions:

• Clitocine represents a novel therapeutic agent for genetic disorders and cancers caused by nonsense mutations.
• It acts through a previously undescribed mechanism to induce nonsense mutation readthrough.
• Clitocine holds promise as a new treatment modality for various diseases.